GlobeNewswire

Stryker declares an $0.88 per share quarterly dividend
07/05/2026
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the [...]
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
07/05/2026
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches Phase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE, [...]
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
07/05/2026
Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91% Gross Margin of 72% and Adjusted EBITDA Growth of 195% Free Cash Flow of $15.1 Million Full-Year 2026 [...]
EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue
07/05/2026
, May 07, 2026 (GLOBE NEWSWIRE) -- EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue Seventh Consecutive Quarter of Year-Over-Year HIFU Revenue Growth 78% Growth in First Quarter HIFU Revenue [...]
Evaxion announces business update and first quarter 2026 financial results
07/05/2026
COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces [...]
Harvard Bioscience to Participate in Upcoming Investor Conferences
07/05/2026
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost’s participation in the following [...]
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
07/05/2026
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by Novo [...]
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
07/05/2026
FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on track for second half [...]
Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
07/05/2026
Enables billing under traditional Medicare and creates a pathway to ~35 million Medicare Advantage beneficiaries through future payer coverage decisions HOUSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc [...]
Ascendis Pharma Reports First Quarter 2026 Financial Results
07/05/2026
- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ® enrollments since early [...]
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
07/05/2026
– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS ® in [...]
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
07/05/2026
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual Meeting First patient dosed in the Phase 2 trial of [...]
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
07/05/2026
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
07/05/2026
PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
07/05/2026
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of [...]
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
07/05/2026
U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug [...]
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
07/05/2026
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Kane Biotech Announces New Private Placement Offering
07/05/2026
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today [...]
Legacy Opens Pasadena Southmore Clinic to Address Critical Health Care Needs
07/05/2026
New two-story clinic brings integrated, affordable care under one roof for Pasadena families HOUSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pasadena gains a new health care lifeline with the opening of the Legacy Pasadena [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum